Komori
Japan Medical Dynamic Marketing (7600) · RiskRestated

Risk of Intellectual Property Infringement and Litigation

First written in FY2016. 2 of 4 entries say "Restated". Latest entry: FY2024.

4entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY2017MitigatedFY20202016: 120162017: 120172018: 020182019: 020192020: 120202021: 020212022: 020222023: 020232024: 12024
Same theme, other companies
Third-Party and Own Intellectual Property Rights Infringement RiskA theme 360 companies write about · 361 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2025: 9 of 59 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 361 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024RestatedAnnual report

    「If products and other goods handled by our group, as well as medical instruments, infringe patents or other intellectual property rights held by other companies, litigation, suspension of sales or payment of damages may result, creating a risk of affecting our profit or loss and financial position. We therefore seek to mitigate these risks by investigating relevant third-party patents and consulting external experts as appropriate during product development.」

    The intellectual property risk and mitigation measures involving searches of third-party patents and consultation with external experts continue to be disclosed.
  2. FY2020MitigatedAnnual report

    「If products and other goods handled by our group, as well as medical instruments, infringe patents or other intellectual property rights, litigation may arise and sales may be discontinued, potentially affecting our profit or loss and financial position. We therefore seek to mitigate these risks by consulting external experts as appropriate during product development.」

    A measure to address the risk of intellectual property infringement by consulting external experts during product development has been specified.
  3. FY2017RestatedAnnual report

    「If products and other items handled by our group infringe the patents or other intellectual property rights of third parties, we may abandon sales or become involved in disputes. Conversely, if we believe that a third party is infringing our group’s patents or other intellectual property rights, we may file a lawsuit to protect those rights. Developments in these matters may affect profit or loss and financial position.」

    Risks relating both to infringement of third-party rights and to protection of our own rights continue to be disclosed.
  4. FY2016First statedAnnual report

    「If products and other items handled by our group infringe the patents or other intellectual property rights of third parties, we may abandon sales or become involved in disputes. Conversely, if we believe that a third party is infringing our group’s patents or other intellectual property rights, we may file a lawsuit to protect those rights. Developments in these matters may affect profit or loss and financial position.」

    The possibility of abandoning sales, becoming involved in disputes and filing lawsuits is disclosed for both infringement of third-party rights and protection of our own rights.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Japan Medical Dynamic Marketing's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Intellectual Property Infringement and Litigation | Japan Medical Dynamic Marketing,INC. (7600) | Komori